Back to Agenda
Session 4: Collaboration with Stakeholders
Session Chair(s)
Abby Bronson, MBA
Vice President, Patient Advocacy and External Innovation
Edgewise Therapeutics, United States
Daniel Millar, MBA
Senior Director, Strategic Business Transformation
Johnson & Johnson, United States
Master protocols promise transformational efficiencies for drug developers while addressing shortcomings of traditional clinical trials which leave clinical trial patients underserved and society waiting for new therapies despite considerable investment. This session explores the importance of stakeholder collaboration to enable evolving the clinical development paradigm and realizing the promised benefits of master protocols. Examples will highlight where stakeholders’ interests align well and where potential tensions must be managed actively through collaboration
Learning Objective : At the conclusion of this session, participants should be able to:- Understand the collaborations required to successfully design, fund, and execute a master protocol
- Establish a master protocol consortium and understand opportunities and challenges
- Collaborate with regulators on innovative clinical development approaches
Speaker(s)
Collaborations with Stakeholders
Abby Bronson, MBA
Edgewise Therapeutics, United States
Vice President, Patient Advocacy and External Innovation
Collaboration with Stakeholders
Victoria Manax Rutson, MD
Pancreatic Cancer Action Network, United States
Chief Medical Officer
Who is LLS
Amy Burd, PhD
Eilean Therapeutics, United States
Chief Scientific Officer
Master Protocols: @FDAOncology View
Gideon M. Blumenthal, MD
Merck & Co., Inc., United States
Vice President Clinical Development Oncology
Daniel Millar, MBA
Daniel Millar, MBA
Johnson & Johnson, United States
Senior Director, Strategic Business Transformation
Have an account?